Goldman Sachs Starts Terns Pharmaceuticals (TERN) at Buy

Goldman Sachs analyst Graig Suvannavejh initiates coverage on Terns Pharmaceuticals (NASDAQ: TERN) with a Buy rating and a price target of $29.00.

For an analyst ratings summary and ratings history on Terns Pharmaceuticals click here. For more ratings news on Terns Pharmaceuticals click here.

Shares of Terns Pharmaceuticals closed at $24.64 yesterday.

You May Also Be Interested In

• DA Davidson Starts Everus (ECG) at Buy
• Truist Securities Starts Matthews International (MATW) at Hold, 'We see risk/reward as more balanced'
• Keefe, Bruyette & Woods Resumes Toronto-Dominion Bank (TD:CN) (TD) at Market Perform